Status:

RECRUITING

Cerebrovascular Health and Resilience in Midlife

Lead Sponsor:

University of Pittsburgh

Collaborating Sponsors:

National Heart, Lung, and Blood Institute (NHLBI)

Conditions:

Psychological Stress

Cardiovascular Diseases

Eligibility:

All Genders

40-59 years

Phase:

NA

Brief Summary

This study examines cardiovascular responses to a brief psychological challenge under laboratory conditions among adult volunteers. The study volunteers are asked to complete two study sessions. In on...

Detailed Description

This cross-sectional study examines the extent to which cardiovascular responses to the acute experience of psychological stress relate to signs of cerebrovascular health detected on magnetic resonanc...

Eligibility Criteria

Inclusion

  • Able to attend 2 study visits at the University of Pittsburgh campus in Oakland (Pennsylvania)
  • Able to read and speak English

Exclusion

  • Uncontrolled hypertension (systolic blood pressure \>160 or diastolic blood pressure \>100 mmHg)
  • Current use of anticonvulsant, anti-Parkinson, neuroleptic, or antipsychotic medications
  • Current use of glucocorticoids (e.g., oral prednisone) or ephedrine
  • Current chronic conditions of the lungs, liver and kidney, as well as cancer (chemotherapy and radiation) treatment in the past 12 months (allowances are made for non-melanoma skin cancer treatment, controlled asthma, and allergy inhalers)
  • Self-reported major neurological disorders or brain injuries (e.g., multiple sclerosis, cerebral palsy, major head injury)
  • Self-reported psychotic illnesses (mania, bipolar disorder, schizophrenia)
  • Current pregnancy or childbirth within the past 6 months
  • Suspected mild cognitive impairment or dementia
  • Self reported sleep apnea
  • Self-reported history of myocardial infarction, stroke, or revascularization procedures, as well as treatment for cardiac arrhythmias
  • Self-reported lack of comfort to undergo MRI testing
  • Presence of implants or objects that are unsafe for MRI (e.g., tattooed eyeliner), as well as any other contraindications that would prevent MRI testing
  • Self-reported lack of comfort to undergo the laboratory math task

Key Trial Info

Start Date :

October 17 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 30 2029

Estimated Enrollment :

450 Patients enrolled

Trial Details

Trial ID

NCT06029348

Start Date

October 17 2023

End Date

June 30 2029

Last Update

September 26 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Pittsburgh

Pittsburgh, Pennsylvania, United States, 15213